Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Prils Market size was valued at USD 2.27 billion in 2024 and is expected to reach USD 5.08 billion by 2037, expanding at around 6.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of prils is evaluated at USD 2.51 billion.
The growth of the market can be attributed to the increasing prevalence of high blood pressure. Lifestyle modifications and appropriate medication, such as prils, are frequently used to treat the disease.
When more people are diagnosed with hypertension and given prescriptions for blood pressure management, in turn, could increase the demand for market. According to estimates over 69 million senior adults in India are expected to have hypertension by the year 2050.
Factors that are believed to fuel the prils market growth include the rise in the pharmaceutical industry across the globe. As more people gain access to the medication, there may be an increase in demand as a result of greater accessibility and availability of prils in hospitals, pharmacies, and other locations.
Prils Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Prevalence of Lifestyle Disorders – As more people with lifestyle disorders rely on drugs to manage their illnesses, the prils market is expected to expand more in the upcoming years. According to the WHO, non-communicable diseases, or NCDs—of which lifestyle illnesses are a subset—take the lives of more than 4o million people each year, or more than 65% of all fatalities worldwide.
- Rising Geriatric Population – Age-related changes in blood vessel flexibility, kidney function, and lifestyle choices all raise the risk of hypertension in older persons. Thus the expanding older population may face a higher prevalence of hypertension, which as a result is estimated to drive market growth. Lately over 8% of the world's population, is over the age of 65. By 2050, this figure is expected to rise by over 15% of the world's population.
- Growing Incidences of Cardiovascular Diseases – It is expected that CVD can develop as a result of unhealthy lifestyle habits including an unhealthy diet, excessive sitting, and a lack of exercise, which is anticipated to drive the prils market growth. It was discovered that with over 17 million deaths per year, cardiovascular diseases (CVDs) are the leading cause of death worldwide.
Challenges
- The challenge to getting Approval from Regulatory Authorities - The acquirement of approval for the production and testing of the product is one of the major factors predicted to slow down the market growth. For instance, it could take a lengthy time to obtain regulatory authorities' clearance, which delays the release of the product.
- Development of Fake Medicines by Several Companies
- Exorbitant Cost of Drugs
Prils Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.4% |
|
Base Year Market Size (2024) |
USD 2.27 billion |
|
Forecast Year Market Size (2037) |
USD 5.08 billion |
|
Regional Scope |
|
Prils Segmentation
Application (Hypertension, Heart Failure, Chronic Kidney Disorder)
The hypertension segment is estimated to hold 50% share of the global prils market in the year 2037. The growth of the segment can be attributed to the increasing cases of hypertension across the globe. As more individuals with hypertension may need medications to control their blood pressure, this could lead to an increase in demand for market.
Besides prils are frequently combined with other antihypertensive drugs to improve blood pressure control which is further expected to contribute to the market growth. Around 970 million people worldwide, or over 25% of the population, have hypertension, and by 2025, that number is projected to rise by over 28%.
Distribution Channel (Hospital, Pharmacies)
Prils market from the hospital segment is expected to garner a significant share of 40% in the year 2037. Prils may be prescribed in hospitals for patients with comorbidities, such as diabetes or chronic renal disease that are frequently linked to hypertension or heart failure. They may be provided as part of the therapy plan for various comorbidities since many individuals admitted to hospitals may have several medical problems. As a result, the demand for prils in hospitals may be expanding along with the prevalence of these comorbidities. As a consequence, multiple opportunities for the segment's growth are expected in the next years.
Our in-depth analysis of the global prils market includes the following segments:
|
Type |
|
|
Distribution Channel |
|
|
Application |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPrils Industry - Regional Synopsis
North American Market Forecast
The prils market in North America is projected to be the largest with a share of about 41% by the end of 2037. The growth of the market can be attributed majorly to the increasing cases of obesity. For instance, the chance of developing hypertension and other cardiovascular disorders increases with obesity, which could result in a rise in the demand for hypertension drugs.
Further, the growing healthcare infrastructure in the region, along with the high prevalence of neurological disorders, is also anticipated to contribute to the market growth in the region. According to estimates, between 2017 and 2020, more than 40% of US people were obese, making it one of the most prevalent health issues in the country.
European Market Statistics
Europe industry is predicted to account for largest revenue share of 31% by 2037. The growth of the market can be attributed majorly to the increasing initiatives to assist the expansion of generic medications through pricing and reimbursement. Generic prils may be used more frequently as a result, which could raise demand for these drugs.
In addition, the region's favorable government policies and surging expenditure on research and development activities are also anticipated to boost market growth during the forecast period.
Companies Dominating the Prils Market
- Teva Pharmaceuticals Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Boehringer Ingelheim International GmbH
- Sun Pharmaceuticals Industries Ltd.
- Pfizer Inc.
- Mylan N.V
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Manus Aktteva Biopharma LLP
- Canagen Pharmaceuticals Inc.
- Lupin Limited
In the News
- Lupin Limited entered into a contract with Medis for Lupin’s orphan drug NaMuscla (mexiletine). Further, for the symptomatic management of people with non-dystrophic myotonic (NDM) diseases, Medis will market NaMuscla in Central and Eastern European nations.
- Novartis AG collaborated with Dr. Reddy's Laboratories which is exclusive for certain of its well-known medications, such as the Voveran range, the Calcium range, and Methergine. Further, the agreement aims to increase patient’s access to these medications beyond present geographic boundaries.
Author Credits: Radhika Pawar
- Report ID: 4109
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
